2012

Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis

Volker Fensterl  
*Cleveland Clinic*

Jaime L. Wetzel  
*Cleveland Clinic*

Srividya Ramachandran  
*Cleveland Clinic*

Tomoaki Ogino  
*Cleveland Clinic*

Stephen A. Stohlman  
*Cleveland Clinic*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**

Fensterl, Volker; Wetzel, Jaime L.; Ramachandran, Srividya; Ogino, Tomoaki; Stohlman, Stephen A.; Bergmann, Cornelia C.; Diamond, Michael S.; Virgin, Herbert W.; and Sen, Ganes C., "Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis." PLoS Pathogens. 8,5. e1002712. (2012). [https://digitalcommons.wustl.edu/open_access_pubs/1315](https://digitalcommons.wustl.edu/open_access_pubs/1315)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
**Interferon-Induced Ifit2/ISG54 Protects Mice from Lethal VSV Neuropathogenesis**

Volker Fensterl¹, Jaime L. Wetzel¹, Srividya Ramachandran¹, Tomoaki Ogino¹, Stephen A. Stohlman², Cornelia C. Bergmann², Michael S. Diamond³, Herbert W. Virgin³, Ganes C. Sen¹*

¹Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, ²Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, ³Departments of Medicine, Molecular Microbiology, and Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America

**Abstract**

Interferon protects mice from vesicular stomatitis virus (VSV) infection and pathogenesis; however, it is not known which of the numerous interferon-stimulated genes (ISG) mediate the antiviral effect. A prominent family of ISGs is the interferon-induced with tetratricopeptide repeats (Ifit) genes comprising three members in mice, Ifit1/ISG56, Ifit2/ISG54 and Ifit3/ISG49. Intranasal infection with a low dose of VSV is not lethal to wild-type mice and all three Ifit genes are induced in the central nervous system of the infected mice. We tested their potential contributions to the observed protection of wild-type mice from VSV pathogenesis, by taking advantage of the newly generated knockout mice lacking either Ifit2 or Ifit1. We observed that in Ifit2 knockout (Ifit2−/−) mice, intranasal VSV infection was uniformly lethal and death was preceded by neurological signs, such as ataxia and hind limb paralysis. In contrast, wild-type and Ifit1−/− mice were highly protected and survived without developing such disease. However, when VSV was injected intracranially, virus replication and survival were not significantly different between wild-type and Ifit2−/− mice. When administered intranasally, VSV entered the central nervous system through the olfactory bulbs, where it replicated equivalently in wild-type and Ifit2−/− mice and induced interferon-β. However, as the infection spread to other regions of the brain, VSV titers rose several hundred folds higher in Ifit2−/− mice as compared to wild-type mice. Surprisingly, this advantage for VSV replication in the brains of Ifit2−/− mice was not observed in other organs, such as lung and liver. Pathogenesis by another neurotropic RNA virus, encephalomyocarditis virus, was not enhanced in the brains of Ifit2−/− mice. Our study provides a clear demonstration of tissue-, virus- and ISG-specific antiviral action of interferon.

**Citation:** Fensterl V, Wetzel JL, Ramachandran S, Ogino T, Stohlman SA, et al. (2012) Interferon-Induced Ifit2/ISG54 Protects Mice from Lethal VSV Neuropathogenesis. PLoS Pathog 8(5): e1002712. doi:10.1371/journal.ppat.1002712

**Editor:** John Hiscott, Vaccine & Gene Therapy Institute of Florida, United States of America

**Received** November 17, 2011; **Accepted** April 5, 2012; **Published** May 17, 2012

**Copyright:** © 2012 Fensterl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by National Institutes of Health grant CA068782. URL: http://grants.nih.gov/grants/oer.htm. The authors declare no competing interests. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: seng@ccf.org

**Introduction**

Virus infection of mammals induces the synthesis of type I interferons (IFN), which, in turn, inhibit virus replication. The high susceptibility of type I IFN receptor knockout (IFNAR−/−) mice to infection by a variety of viruses [1–3] provides strong evidence for the major role of the IFN system in protecting from viral pathogenesis. In these mice, although IFN is induced by virus infection, it cannot act on target cells. Similarly, in genetically altered mice that are defective in IFN production due to the absence of specific pathogen-associated pattern recognition receptors, signaling proteins or specific transcription factors, viral pathogenesis is enhanced [4–6]. Although the critical importance of the IFN system in regulating viral pathogenesis is now well established, in many cases it is still unclear how IFN inhibits the replication and spread of a specific virus in vivo. In this context, activation of different components of the immune system plays a major role in controlling viral diseases that are relatively slow to develop [7–9]. In contrast, in acute infection by viruses that cause severe pathogenesis and death within a few days after infection, protection is primarily provided by the intrinsic antiviral actions of IFN-induced proteins encoded by the hundreds of IFN-stimulated genes (ISGs) [10–12], several of which often contribute to the overall effect of IFN against a given virus. Our knowledge of the antiviral and the biochemical properties of individual ISG products is mostly limited to a few intensively studied examples such as PKR, OAS/RNase L or Mx [13]. However, recent systematic investigation of the antiviral functions of the entire family of ISGs has started producing exciting new information [14].

In the above context, we have been investigating the biochemical and biological functions of the members of the ifi family of ISGs, which are very strongly induced by IFN. There are three members of this family of genes in mice: Ifit1/ISG56, Ifit2/ISG54 and Ifit3/ISG49; all of the encoded proteins contain multiple tetratricopeptide repeats (TPR), which mediate protein-protein and protein-RNA interactions [15]. In vitro, P56 and P54, the products of Ifi1 and Ifi2, respectively, bind to the translation initiation factor eIF3 and inhibit protein synthesis [16]. The third member, P49, the product of Ifi3, does not share this property.
Author Summary

In mammals, the first line of defense against virus infection is the interferon system. Viruses induce synthesis of interferon in the infected cells and its secretion to circulation. Interferon acts upon the as yet uninfected cells and protects them from oncoming infection by inducing the synthesis of hundreds of new proteins, many of which interfere with virus replication. Vesicular stomatitis virus (VSV), a virus similar to rabies virus, is very sensitive to interferon but it is not known which interferon-induced protein inhibits its replication. Here, we have identified a single interferon-induced protein as the protector of mice from death by VSV infection. Knocking out the gene encoding this protein, Ifit2, made mice very vulnerable to neuropathogenesis caused by VSV infection; a related protein, Ifit1, did not share this property. Moreover, Ifit2 failed to protect mice from another neurotropic virus, encephalomyocarditis virus, nor was it necessary for protecting organs other than brain from infection by VSV. Our observation that a single IFN-induced protein protects a specific organ from infection by a specific virus revealed an unexpected degree of specificity of the antiviral action of IFN.

[17]. Recently, it has been reported that Ifit proteins form a multi-protein complex that can bind to the triphosphorylated 5’ end of RNAs, an RNA-species produced during the replication of some, but not all, viruses [18]. In vivo, these genes are strongly induced in brains of mice infected with West Nile virus (WNV) or Lymphocytic choriomeningitis virus (LCMV); surprisingly, different Ifit genes are differentially induced in different regions of the brain, suggesting non-redundant functions [19]. To further explore the antiviral properties of the Ifit proteins, we generated Ifit1 knockout (Ifit1−/−) mice and challenged them with different viruses. We observed that Ifit1−/− mice were particularly susceptible to a WNV mutant that is defective in its mRNA cap 2′-O methylation; the mutant virus killed Ifit1−/− mice but not the wild-type (wt) mice [20].

Here, we report on the antiviral properties of the newly generated Ifit2−/− mice; these mice, but not Ifit1−/− mice, were highly susceptible to neuropathogenesis after intranasal infection with vesicular stomatitis virus (VSV), a negative sense, single-stranded RNA rhabdovirus. VSV replication is highly sensitive to interferon but it is not known which interferon in the infected cells and its secretion to the extracellular milieu (IFN) is the interferon system. Viruses induce synthesis of hundreds of new proteins, many of which interfere with virus replication. Vesicular stomatitis virus (VSV), an enveloped, negative-sense, single-stranded RNA virus, is very sensitive to interferon but it is not known which interferon-induced protein inhibits its replication. Here, we have identified a single interferon-induced protein as the protector of mice from death by VSV infection. Knocking out the gene encoding this protein, Ifit2, made mice very vulnerable to neuropathogenesis caused by VSV infection; a related protein, Ifit1, did not share this property. Moreover, Ifit2 failed to protect mice from another neurotropic virus, encephalomyocarditis virus, nor was it necessary for protecting organs other than brain from infection by VSV. Our observation that a single IFN-induced protein protects a specific organ from infection by a specific virus revealed an unexpected degree of specificity of the antiviral action of IFN.

Results

Generation of Ifit2/ISG54 and Ifit1/ISG56 knockout mice

Ifit2 gene knockout (Ifit2−/−) mice were generated by deleting the entire protein-coding region of the gene, which was achieved by flanking exons 2 and 3 with Flp recombinase sites in C57BL/6 embryonic stem cells and excising the flanked region with Flp recombinase (Figure 1A). Ifit2−/− mice were bred to homozygosity (Figure 1B), and deficiency for induced expression of Ifit2 protein was confirmed in lysates of IFN-β-treated primary murine embryonic fibroblasts (MEF) (Figure 1C). Mice deficient for Ifit1 (Ifit1−/−) were derived from C57BL/6 embryonic stem cells lacking the entire Ifit1 coding region (Figure 1A). Genotypic homozygosity of the Ifit1−/− mice and deficiency for Ifit1 protein induction were confirmed (Figure 1B and 1C). Both knockout mouse lines were healthy and fertile. Moreover, deletion of one gene within the Ifit locus did not alter the pattern of induction of other adjacent gene family members, as compared to wild-type (wt) mice (Figure 1C).

Ifit2 protects mice from lethal intranasal VSV infection

To determine the impact of Ifit2 on the outcome of viral infections in vivo, we compared susceptibilities of Ifit2−/− and wt mice to VSV infection, using IFNAR−/− mice as positive controls of enhanced susceptibility. Virus was administered at a low dose [4 × 102 plaque forming units (pfu)], intranasally, reflecting a natural route of infection for VSV [22]. As seen previously, 100% of IFNAR−/− mice rapidly succumbed to VSV infection within 2 days (Figure 2A, and [1]), after suffering symptoms of lethargy. On the other hand, 79% of wt mice survived, the remaining 21% succumbed to VSV, and this occurred later, at 7–10 days post infection (d.p.i.). In contrast, 100% of Ifit2−/− mice died by 7 d.p.i. (Figure 2A), with most succumbing by 6 d.p.i.; thus, we observed uniform and more rapidly occurring death of Ifit2−/− compared to wt mice after VSV infection. Within 24 h before death, both wt and Ifit2−/− mice developed neurological signs including ataxia, hind limb paralysis, and hyper-excitability. Ifit2−/− mice displayed an intermediate survival curve, demonstrating a gene dosage effect (Figure 2B). Next, the role of a related gene, Ifit1, in VSV pathogenesis was evaluated by infecting Ifit1−/− mice. Unlike the results observed with Ifit2−/− mice, no statistically significant increase in mortality was observed in Ifit1−/− mice (Figure 2B, 21% death for wt versus 36% for Ifit1−/−, respectively; p > 0.25). Consistent with this, survival kinetics of Ifit1−/− and wt mice were similar. Increasing the virus dose by 10,000-fold (to 4 × 104 pfu) did not appreciably change the survival curves of wt, Ifit1−/−, or Ifit2−/− mice (Figure 2C). These results demonstrate functional differences between the two closely related proteins encoded by Ifit1 and Ifit2. The virus-specificity of the antiviral action of Ifit2 was evaluated by infecting Ifit2−/− mice with EMCV, an unrelated neuroviral positive-strand RNA virus of the picornavirus family (Figure 2D). IFNAR−/− mice were highly susceptible to EMCV infection with all mice succumbing within 2 d.p.i.; in contrast, wt mice died with a slower kinetics and at a rate of only 80%. Notably, Ifit2−/− mice behaved similarly to the wt mice, without enhanced or accelerated mortality (Figure 2D). The same conclusion was true for a lower dose of EMCV (Figure S1). The survival pattern of EMCV-infected Ifit1−/− mice also was similar to that of the wt mice (Figure 2D). Mice of all genotypes either succumbed after developing neurological symptoms, mainly hind limb paralysis, or survived without symptoms. These results demonstrate that the antiviral action of Ifit2 is both virus- and Ifit-specific.

Ifit2 does not inhibit VSV entry and replication in olfactory bulbs

The uniform penetrance of neuropathogenesis and lethality of VSV-infected Ifit2−/− mice, even at a low virus dose, prompted us to examine viral spread along its route from the nasal cavity into the CNS (Figure 3A). After intranasal administration, VSV infects...
Figure 1. Generation of Ifit2/ISG54 and Ifit1/ISG56 knockout mice. A, gene targeting strategy for genomic deletion of complete protein-encoding regions of Ifit2 = ISG54 or Ifit1 = ISG56 in embryonic stem cells; TAG/TGA, stop codons; grey boxes = exons. B, genotyping of deficiency for Ifit2 or Ifit1 by PCR on mouse tail DNA. C, IFN-β-induced protein expression of Ifit2/P54, Ifit1/P56 and Ifit3/P49 in Ifit2−/− or Ifit1−/− primary MEFs.

Figure 2. Ifit2 protects mice from lethal intranasal VSV infection. A, survival of Ifit2−/−, IFNAR−/− and wt mice after intranasal infection with 4 × 10^2 pfu of VSV Indiana. B, survival of Ifit1−/− and Ifit2-heterozygous (Ifit2+/−) mice after infection with 4 × 10^2 pfu of VSV; experiments in A and B shared wt mice (n = number of animals used). C, survival of Ifit2−/−, Ifit1−/− and wt mice after intranasal infection with a higher dose of VSV (4 × 10^6 pfu). D, survival of Ifit2−/−, Ifit1−/−, IFNAR−/− and wt mice after infection with 5 × 10^2 pfu of EMCV. In A–D, data are cumulative from at least two independent experiments (exceptions: Figure 2B, Ifit2+/− mice and Figure 2D, Ifit1−/− mice infected in a single experiment). Statistical significance of survival differences relative to wt mice is indicated by p-values; n.s., not significant; i.n., intranasal.

doi:10.1371/journal.ppat.1002712.g001

doi:10.1371/journal.ppat.1002712.g002
the nasal epithelia including olfactory sensor neurons, which project to the outer layer of the olfactory bulbs (OB) [23]. This represents the entry step into the CNS, which we examined by immunostaining of OB sections. In wt mice, VSV P protein was detected exclusively within the glomeruli of the OB at 2 d.p.i. (Figure 3B, upper right panel and [1]), whereas in IFNAR−/− mice, VSV antigen had spread into deeper layers of the OB (Figure 3B, lower left panel). In Ifit2−/− mice OB, viral antigen was restricted to the glomeruli, as seen in wt mice (Figure 3B, lower right panel). This similar pattern of viral antigen expression between wt and Ifit2−/− mice was reflected in the equivalent levels of viral RNA in OB at 2 d.p.i. (Figure 3C). In contrast, 10 times more VSV RNA was present in OB of IFNAR−/− mice (Figure 3C, right panel, p<0.05). A comparison of the infectious viral burden between wt and Ifit2−/− mice in the OB confirmed these findings: at 2 d.p.i., ∼10^5 pfu/g of VSV was present in both wt and Ifit2−/− mice (Figure 3D, p = 1.0).

However, later in the course of infection, by day 6, viral OB titers in Ifit2−/− mice were not significantly changed, whereas in wt mice average titers of infectious VSV as well as viral RNA levels had decreased by ∼10-fold (Figure 3C and D, both p<0.05). These results suggest that VSV initially enters and replicates with similar efficiency in both wt and Ifit2−/− OB before spreading into the rest of the brain.

**Ifit2 suppresses replication of VSV in the brain after intranasal infection**

The efficiency of VSV replication in the brain, excluding the OB, was examined by quantifying infectious VSV as well as viral RNA. Early after infection, at 2 d.p.i., virus titers in brains were low (∼10^4 to 10^5 pfu/g) and roughly equivalent in wt and Ifit2−/− mice (Figure 4A, p=0.25). Similarly, viral RNA levels at the same

---

**Figure 3. Ifit2 does not inhibit VSV entry and replication in olfactory bulbs.** A, schematic entry route of VSV into the central nervous system of wt mice after intranasal infection, and VSV spread within brain, as reported in the literature. OB, olfactory bulbs; CX, cortex; MB, midbrain; CB, cerebellum; BS, brain stem; SC, spinal cord. B, VSV P protein in OB of VSV-infected wt, Ifit2−/− and IFNAR−/− mice at 2 d.p.i., detected by immunohistofluorescence. C, VSV RNA levels in OB of uninfected or VSV-infected wt, Ifit2−/− and IFNAR−/− mice at 1, 2 or 6 d.p.i., plotted as mean±SD on log scale; ND, none detected. D, infectious VSV titers in wt and Ifit2−/− OB at 2 and 6 d.p.i.; plotted as pfu/g with mean on log scale; dashed line depicts threshold of detection. In C and D, n = 4-8 mice per infected group accumulated from three independent experiments; in B, n = 2 mice from two independent experiments. All infections were 4×10^2 pfu of VSV administered intranasally. Asterisks indicate statistical significance: ** p = 0.006, * p<0.05; n.s.: not significant.

doi:10.1371/journal.ppat.1002712.g003
Ifit2 and Ifit1 are induced in VSV-infected regions of OB and brain

The protective effect of type I IFN signaling and in particular, Ifit2, against VSV neuropathogenesis prompted us to confirm its expression in OB and brain of wt mice, and whether it was induced in a type I IFN-dependent manner. In wt OB, Ifit2, Ifit1, and IFN-β mRNA was induced strongly by 2 d.p.i., and Ifit2 and Ifit1 RNA remained abundant until day 6 d.p.i. [Figure 5A]. The induction of these genes was dependent on type I IFN receptor in OB as well as in brain (Figure 5B and 5E, and data not shown).
Furthermore, expression of Ifit2 mRNA in wt OB coincided with the presence of detectable levels of the encoded Ifit2 protein \((=P54)\) at 2 d.p.i. and 6 d.p.i., as seen by immunohistochemistry (Figure 5C, and data not shown). Ifit2 protein staining was observed in VSV-infected cells within OB glomeruli as well as in surrounding and distal viral antigen-free cells, consistent with a remote IFN-dependent induction of Ifit2 expression (Figure 5C, arrowsheads in magnified images of right panel). Ifi1 and IFN-β mRNAs were induced as strongly in OB of Ifit2/−/− as in wt mice, which correlated well with similar abundance of VSV RNA in wt and Ifit2/−/− OB (Figure 5A compared to Figure 3C). In brains, at 6 d.p.i., in contrast to OB, induction of Ifi1 and IFN-β mRNAs was considerably stronger in Ifit2/−/− mice compared to wt mice (Figure 5D, 5-fold and 27-fold, respectively, both \(p<0.005\)). The enhanced gene induction in VSV-infected Ifit2/−/− mice was not restricted to specific regions of the brain (Figure S2). Enhanced cellular gene expression also was observed for several virus-induced cytokine and chemokine genes, as measured by quantitative RT-PCR (Figure S3A). Gene expression profiling of brain tissue at day 6 d.p.i., using microarray analysis, revealed that many other genes, including ISGs, were also more strongly induced (Table S1). These results demonstrated that enhanced virus replication in the brains of Ifit2/−/− mice led to enhanced type I IFN, other cytokines and ISG induction, which nevertheless failed to restrict VSV replication in the absence of Ifit2.

Wt mice are as susceptible as Ifit2/−/− mice to intracranial VSV infection.

Our results from intranasal VSV infection indicated that Ifit2 induction in the brain was mediated by type I IFN that was, in all likelihood, produced by infected cells in the OB (Figure 5A). Virus replication and resultant IFN induction at 2 d.p.i. were similar in the OBs of wt and Ifit2/−/− mice (Figs. 3C, 3D and 5A); presumably, the newly produced IFN diffused into the rest of the brain and induced local Ifit2 expression in the wt mouse brains, prior to the arrival of the infectious virus. If this were the case, one would anticipate that direct injection of the brain, without prior action of IFN produced in infected OB, would minimize the difference between the phenotypes of wt and Ifit2/−/− mice. To test this idea, we injected a very low dose \((10\ \text{pfu})\) of VSV intracranially. As hypothesized, wt and Ifit2/−/− mice were now equally susceptible; almost all mice died by 3 d.p.i. even at this low dose (Figure 6A) and there were equally high virus titers and viral RNA levels in the brains of mice of both genotypes (Figure 6B and 6C). Concomitant with virus replication, there was similar induction of Ifit1 and IFN-β (Figure 6C) and other cytokines and chemokines (Figure S3B). These results indicate that in the absence of prior induction of Ifit2 by IFN, brain neurons are highly susceptible to VSV infection.

Unlike the brain, other organs of Ifit2/−/− mice are not more susceptible to intranasal VSV infection.

Ifit2/−/− mice succumbed within two days after VSV infection without accumulating very high VSV RNA levels in the brain (Figure 4B). These mice did not develop CNS-related signs of disease, but showed severe lethargy before death, suggesting that death was due to efficient replication of the virus in peripheral organs, due to the absence of an otherwise effective type I IFN-mediated antiviral protection of the same organs in wt mice. To test this, we assessed the kinetics of VSV accumulation in brains, livers and lungs of wt, Ifit2/−/− and Ifit2/−/− mice (Figure 7). At 2 d.p.i., VSV titers were very high in the liver of Ifit2/−/− mice, reaching \(10^9\ \text{pfu/g}\) (Figure 7A). In contrast, no or little infectious virus was detected in the liver of wt mice at 2 or 6 d.p.i., indicating efficient IFN-dependent suppression of VSV replication; intriguingly, this was also observed in Ifi2/−/− mice, demonstrating that Ifit2 did not mediate the anti-VSV effects of type I IFN in the liver. In lungs, which directly received a part of the virus inoculum from intranasal inhalation of VSV, the virus also replicated efficiently in Ifnar−/− mice, reaching \(10^6\ \text{pfu/g}\) before death (Figure 7B). In comparison, lungs of wt and Ifit2/−/− mice exhibited much lower levels of VSV at 2 and 4 d.p.i. \((3,000\ \text{to} 10,000\text{-fold lower for wt and Ifit2/−/− compared to Ifnar−/− mice, all } p<0.05)\). By days 5 and 6 d.p.i., the virus was cleared from the lungs of a subset of wt and Ifit2/−/− mice. In contrast, in brains from the same animals, 10 to 100-fold higher average titers \((p<0.05)\) of VSV accumulated in Ifit2/−/− compared to wt mice at all time points between 2 and 6 d.p.i. (Figure 7C). As expected, in wt mice, both Ifit1 and Ifit2 were induced not only in brains (Figure 5D), but also in livers (Figure 7D) and lungs (Figure 7E); IFN-β was also induced in lungs, but not livers. Ifi1, Ifit2 and IFN-β mRNAs were also induced in the brains of EMCV-infected wt mice (Figure S3C). These findings demonstrate an unexpected brain-restricted and virus-restricted function of Ifit2 in the context of the type I IFN-mediated antiviral response to VSV infection. They also indicate that in Ifit2/−/− mice, other ISGs, which presumably protect the peripheral organs of VSV-infected wt mice, are either not induced in neurons or insufficient to protect them.

Discussion

IFNs are defined by their antiviral activities. They inhibit the replication of many, if not all, viruses mostly by direct inhibition of replication in the infected cells but also by promoting the ability of immune cells to recognize and eliminate the virus-infected cells [25]. The direct effects are mediated by ISGs, which number in the hundreds, and different ISGs are thought to have more potent antiviral activities toward different families of viruses [13]. However, in most cases, it is not known which ISG inhibits the replication of a given virus; the rare exception is the Mx-mediated inhibition of influenza viruses, the underlying effect which allowed for the discovery of IFNs [26]. The task of connecting a specific IFN-induced protein to a specific antiviral action is compounded by the fact that often several IFN-induced proteins act in concert to inhibit the same virus at different stages of its life cycle. Moreover, a specific IFN-induced protein may be more relevant for inhibiting a virus in one specific cell-type than another. Recent systematic investigation of the specific antiviral effects of different ISGs has started providing significant insight into this problem [14]. Such findings are complemented by the analyses of the spectra of the antiviral effects of a specific ISG or a family of ISGs [27]. We have undertaken an investigation of the Ifit family of mouse ISGs. The corresponding human proteins are known to have antiviral activities against human papillomavirus (HPV) and hepatitis C virus (HCV), neither of which replicate in mouse cells. The anti-HPV activity of human IFIT1 \((=P56)\) has been attributed to its ability to bind HPV E1 protein and to inhibit its helicase activity, which is essential for HPV DNA replication [28,29]. The antiviral effect on HCV, on the other hand, is manifested at the level of inhibiting viral protein synthesis as a consequence of the ability of IFIT1 to bind the translation initiation factor eIF3 and inhibit its various actions in translation initiation [30]. It has been reported recently that the IFIT1 protein can form a complex and bind to RNAs with triphosphorylated 5’ ends, presumably providing another means to inhibit specific viruses that produce such RNAs [18].
The Ifit genes are clustered at a single locus in both human and mouse. In the latter species, two alleles of Ifit genes are flanked on two sides by one allele of Ifit2 and one allele of Ifit1 [15]. To identify their physiological functions, we have separately deleted the entire coding regions of Ifit1 or Ifit2 genes. The Ifit1−/− mice exhibited an interesting phenotype in allowing the replication of and resultant pathogenesis by a WNV mutant, which failed to replicate in wt mice [20]. Because this mutant is defective in 2′-O-methylation of the cap structure of viral mRNAs, its rescue in the Ifit1−/− mouse indicates that this antiviral protein recognizes the 5′ ends of mRNAs, a conclusion that is consistent with the observation that, in vitro, it can bind to RNAs having specific structures at the 5′ ends [18]. It remains to be seen whether the proposed property of Ifit proteins to recognize 5′ ends of RNA is

Figure 5. Ifit2 and Ifit1 are induced in VSV-infected regions of OB and brain. A/B, D/E. Ifit2, Ifit1 and IFN-β mRNA levels in OB (A, B) and separated brains (D, E) of uninfected or intranasally VSV-infected wt, Ifit2−/− and IFNAR−/− mice at 2 or 6 d.p.i., plotted as mean±SD. The same OB and brains were also assayed in Figure 3C and 4B for VSV RNA levels. In A/B/D/E: n = 4–8 mice per infected group accumulated from three independent experiments; ND, none detected. C. Ifit2 (P54) protein in wt OB sections, uninfected or 2 d.p.i., with parallel detection of VSV P protein in adjacent sections, detected by immunohistochemistry; arrowheads indicate Ifit2-positive, VSV-negative cells surrounding the glomeruli; n = 2 mice. All infections were intranasal with 4×10^2 pfu of VSV. Asterisks indicate statistical significance: ** p<0.005, *** p<0.0005; n.s.: not significant. doi:10.1371/journal.ppat.1002712.g005
connected in any way to their ability to inhibit the functions of eIF3 [16], which participates in several steps of translation initiation taking place at or near the 5′ ends of mRNAs.

Replication of VSV is highly sensitive to the antiviral activity of IFNs, and VSV is widely used to determine the specific activities of IFN preparations quantitatively [21]. In spite of this strong connection, it is unclear how IFN inhibits VSV replication. An early report indicated that viral primary transcription is inhibited by IFN, but it is not known which IFN-induced protein mediates this inhibition [31]. The observed sensitivity of VSV replication in vitro is reflected in vivo. IFNAR−/− mice are extremely susceptible to VSV infection; they rapidly die within 2 days after infection and the virus replicates to very high titers in many organs of the infected mice. The extreme sensitivity of IFNAR−/− mice to VSV infection suggests that type I IFN provides the majority, if not all, of the protective innate immune defense. Eventually, protection may be facilitated by immune cell-mediated antiviral actions, but this is a slow process that does not appear to function before 6–10 days post-infection [32,33]. Thus, it is likely that one or more ISGs directly inhibit VSV replication in vivo. In this context, it has been reported that mice lacking PKR, a well-studied ISG, display higher susceptibility to VSV pathogenesis [34]. However, detailed investigation of the underlying mechanism revealed that PKR did not execute IFN’s antiviral action; rather, it was required for efficient induction of IFN-α/β in the infected mice [35].

Our results show that Ifit2−/− mice are highly susceptible to intranasal VSV infection and the effect is gene dosage-dependent: Ifit2−/− mice had an intermediate susceptibility phenotype. Infected Ifit2−/− mice displayed symptoms of severe neuropathogenesis late after VSV infection accompanied by efficient replication of the virus in many regions of the brain. However, virus replication was restricted to neurons and did not spread to other types of cells in the brain, such as astrocytes. Our results are consistent with the hypothesis that prior, IFN-induced, Ifit2 expression in the brain restricts VSV replication. Supporting genetic evidence for the requirement of IFN action is provided by the high susceptibility of the IFNAR−/− mice, which possess the functional Ifit2 gene but Ifit2 is not induced by VSV infection because these mice cannot respond to type I IFN. Additional evidence comes from a previous study using brain-specific IFNAR−/− mice, which displayed a pattern of susceptibility to intranasal VSV infection similar to that of our Ifit2−/− mice [1]. In our experimental system, the source of the IFN production was
most likely the OBs; abundant IFN was induced there early (2 d.p.i.) after infection (Figure 5A) causing the induction of Ifit2 in wt mice (Figure 5C). Ifit2 was also induced at this time in the rest of the brain, without any induction of IFN mRNA (Figure 5D) suggesting that the source of IFN was the OB. In accord with the well-established concept of IFN action, pre-induction of Ifit2 in neurons, before the onset of infection, was essential for the antiviral effect. In comparison, induction of IFN and Ifit2 that was concomitant with VSV infection failed to have an appreciable antiviral effect, as manifested by robust virus replication at directly infected sites, such as the OBs of wt mice infected intranasally (Figure 3D) or the brain of wt mice infected intracranially (Figure 6B). High mortality of the infected mice correlated with high virus titers in the brains of intranasally infected Ifit2−/− mice or intracranially infected wt and Ifit2−/− mice. In the intranasally infected Ifit2−/− mice, death was not preceded by widespread apoptosis in the brain (Figure S4). However, as expected with high viral loads, IFN and other cytokines and chemokines were strongly induced (Figures 5D, S2 and S3A); consequently, many ISGs, except Ifit2, were also induced (Table S1).

Pre-induced Ifit2 prevents efficient VSV replication in the brain, most probably by blocking one or more essential step of the viral life cycle including viral entry, uncoating, primary transcription, viral protein synthesis, RNA replication, virion assembly or egress. It also might block trans-synaptic spread of the virus, although unlike another rhabdovirus, rabies virus, VSV is not known to depend on transit from neuron to neuron. In this context, it is important to note the observations made by Iannacone et al. [37]

Figure 7. Unlike the brain, other organs of Ifit2−/− mice are not more susceptible to intranasal VSV infection. A–C, infectious VSV titers in organs of wt, Ifit2−/− or IFNAR−/− mice (n = 4–10 mice per group accumulated from three independent experiments) at 2, 4, 5 and 6 days after intranasal infection; livers (A), lungs (B) and brains (C, incl. OB) of the same mice were assayed and plotted as pfu/g with mean; not all available livers were titered. Dashed line depicts threshold of detection. D/E, Ifit2, Ifit1, IFN-β mRNA levels in livers (D) and lungs (E) of uninfected or VSV-infected wt mice at 2 d.p.i., plotted as mean±SD; n = 4 mice per infected group; ND, none detected. All infections were intranasal with 4 × 10^4 pfu of VSV. Asterisks indicate statistical significance: * p<0.05, ** p<0.005.

doi:10.1371/journal.ppat.1002712.g007
using a footpad VSV infection model. They concluded that type I IFN, produced by infected macrophages and plasmacytoid dendritic cells in infected mice, blocked infection of peripheral neurons resulting in lowered infection of the CNS and prevention of neuropathogenesis. It is worth noting that in our studies, the absence of Ifit2 did not affect IFN induction by VSV (Figures 5A and 6C). Further investigation of the biochemical mechanism behind the observed in vivo effect of Ifit2−/− is hampered by the absence of a suitable cell culture model of the phenomenon. For example, Ifit2 was not required for mediating the anti-VSV effect of IFN in mouse embryonic fibroblasts (Figure S5), in primary fetal neurons or in Ifit2-ablated neuroblastoma cells (data not shown), results that are not surprising given the strong tissue-specificity of Ifit2 action observed in vivo (Figure 7). Specific RNA-binding properties of Ifit proteins have been recently reported [18]. Following this lead, we examined the RNA-binding properties of recombinant murine Ifit1 and Ifit2 using VSV leader RNA as the probe in an electrophoretic mobility shift assay: Ifit1 bound RNA with a 5′-ppp end but not with a 5′-OH end; however, Ifit2 bound neither (Figure S6). To obtain meaningful leads, future investigation of this kind may require using brain extracts from infected mice to detect protein-viral RNA complexes that may contain Ifit2 along with adult neuron-specific proteins.

Our results revealed several layers of specificity of IFN action, some of which were not anticipated. First, compared to Ifit2−/− mice, Ifit1−/− mice were much less susceptible to intranasal VSV infection; this was true for both low and high doses of virus. This finding was surprising in view of a recent report on VSV susceptibility of Ifit1−/− mice [18] and the observation that Ifit1, but not Ifit2, could bind VSV leader RNA in vitro (Figure S6). The above results demonstrate that different Ifit proteins have non-redundant functions in vivo. The second layer of specificity was directed toward the nature of the infecting virus. Although both VSV and EMCV caused neuroinvasive disease, induced IFN-β, Ifit1 and Ifit2 in the brain and type I IFN action was required for protection against both viruses, Ifit2 was critical only for protection against VSV; the absence of either Ifit1 or Ifit2 did not exacerbate susceptibility to EMCV. The third layer of specificity was revealed by the organ-specific action of Ifit2. In the complete absence of type I IFN action in the IFNAR−/− mice, intranasally infected VSV replicated vigorously not only in brains, but also in livers and lungs (Figure 7A–C). In contrast, in Ifit2−/− mice, efficient VSV replication was restricted to the brain suggesting that Ifit2 does not act as an anti-VSV ISG in the liver or the lung because its absence did not impact virus titers, even though Ifit2 was induced in these organs of infected wt mice (Figure 7D and 7E). The efficient VSV replication in livers and lungs of IFNAR−/− mice, but not wt and Ifit2−/− mice, indicates that other ISGs must have anti-VSV effects in those organs. Further investigation is needed to determine the basis of neuronal specificity of Ifit2 action and the identities of other ISGs that inhibit VSV replication in other organs.

**Materials and Methods**

**Ethics statement**

All animal experiments were performed in strict accordance with all provisions of the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the PHS Policy on Humane Care and Use of Laboratory Animals. The protocol was approved by the Cleveland Clinic Institutional Animal Care and Use Committee (IACUC), PHS Assurance number A3047-01. All experimental manipulations or intranasal instillations of mice were performed under anesthesia induced by pentobarbital sodium or isoﬂuoran, respectively, and all efforts were made to minimize suffering.

**Mice**

All mice used were of C57BL/6 background and of both sexes; Ifit2−/− mice were custom-generated by Taconic Farms, Inc. by flanking exons 2 and 3 of Ifit2, encompassing the complete protein-encoding region, with fit sites in C57BL/6 embryonic stem (ES) cells, and deleting the flanked region by transfection of Flp recombinase. ES cell clones were injected into BL/6 blastocysts, and heterozygous offspring mice were crossed to homozygosity. Ifit2−/− mice were generated from C57BL/6 ES cells lacking the whole coding region of Ifit2 (20); ES cells were obtained from the NIH Knockout mouse project (KOMP, allele Ifit2−/−). The same ES cell line was independently used to generate mice in another study [18]. IFNAR−/− mice (lacking Ifnar1) were a gift of Murali-Krishna Kaja (Emory University, Atlanta, GA). Congenic wild-type mice were obtained from Taconic Farms.

**Viruses and infections**

Vesicular stomatitis virus (VSV) Indiana was a gift from Amiya K. Banerjee, Lerner Research Institute, Cleveland, Ohio. For intranasal infections, between 4×10^2 and 4×10^2 pfu of VSV in 35 μl of endotoxin-free PBS were injected by isoflurane-anesthetized 8–12 week-old mice, with PBS-only as control. For intracranial infections, 10 pfu of VSV in 30 μl of endotoxin-free PBS were injected into the brains of 6–7 week-old mice, with PBS-only as control. Thereafter, mice were monitored daily (twice daily after i.c. injection) for weight loss and symptoms of disease. Encephalomyocarditis virus (EMCV) K strain was a gift from Robert H. Silverman, Lerner Research Institute, Cleveland, Ohio. For intraperitoneal infections, between 25 and 5×10^5 pfu of EMCV in 500 μl of PBS were injected into the peritoneal cavity of mice. Mice were monitored daily for weight loss and symptoms of disease.

**Immunohistochemistry and TUNEL assay**

Mice were anesthetized with pentobarbital (150 mg/kg) and blood was removed from organs by cardiac perfusion with 10 ml of PBS, followed by perfusion with 10 ml of 4% paraformaldehyde/PBS for fixation. Brains were placed in 4% paraformaldehyde overnight for complete fixation, submerged in 30% sucrose/PBS for fixation. Brains were placed in 4% paraformaldehyde overnight for complete fixation, submerged in 30% sucrose/PBS overnight for cryoprotection, and frozen in O.C.T. compound (Sakura Finetek USA, Torrance, CA, USA). 10 μm sagittal sections were cut at −20°C in a Leica CM1900 cryostat, mounted on coated slides (Superfrost Plus, Fisherbrand, Fisher Scientific); membranes were permeabilized by 0.2% Triton X-100/PBS treatment for 15 min. For immunohistochemistry, the Envision+ DAB kit (Dako, Carpinteria, CA) was used with anti-mouse Ifit2/PS5 [38] or anti-VSV-P protein (a gift from Amiya K. Banerjee, Lerner Research Institute, Cleveland, Ohio) as primary antibodies. For immunofluorescence, anti-VSV-P or anti-NeuN (Chemicon Int./Millipore, Billerica, MA) or anti-GFAP (Sigma-Aldrich, St. Louis, MO) were used; labeled brain sections were stained with AlexaFluor-594 secondary antibody (Invitrogen/Molecular Probes, Carlsbad, CA). For detection of apoptotic cells in brain sections, the DeadEnd fluorometric TUNEL system (Promega) was used according to manufacturer’s instructions. All objects were then mounted with VectaShield (with DAPI, Vector Labs, Burlingame, CA), and examined with a Leica DMR fluorescence microscope.
Quantitative RT-PCR and microarray analysis

Mice were anesthetized with pentobarbital (150 mg/kg) and blood was removed from organs after cardiac perfusion with 10 ml of PBS. Brains were separated into olfactory bulbs and the remainder of the brain, snap-frozen in liquid nitrogen (as well as livers and lungs) and RNA was extracted using TRIzol reagent (Invitrogen). DNase I treatment (DNAfree, Applied Biosystems/Ambion) and reverse transcription with random hexamers (Invitrogen, Promega) were performed according to manufacturer’s instructions. 0.5 µg of RNA was used in 30 µl real-time PCRs in a Roche LightCycler 480 II using Applied Biosystem’s SYBR Green PCR core reagents. PCR primers for murine ISG49/Ifit3, ISG54/Ifit2, ISG56/Ifit1 and ISG58 rRNA have been published previously [17]; primers targeting murine Ifib1 [5'-CTTCTCCTGTCATCTGG-3'] [39], with the alternative reverse primer: 5'-CACAGGCCCTCTCATCAACT-3'], VSV N RNA [40] or EMCV 3D polymerase genomic region [41] were described previously. Primers for Ccl2, Il1b, Il6, Tnf; Il12b and NOS2 have been described previously [42,43]. Average expression levels, relative to 18S rRNA and normalized by use of calibrator samples, were graphed with Prism 5.02 software. For analysis of different regions of the brain, brains without OB of perfused mice were separated into cortex, cerebellum, brain stem and remaining “midbrain”, and tissue was submersed into RNAlater stabilizing reagent (Qiagen) overnight and frozen. RNA was then extracted via TRIzol and further processed and assayed by real-time RT-PCR as described above. For microarray analysis, TRIzol-extracted and DNase I-treated RNA was additionally purified using spin columns (RNeasy Mini kit, Qiagen) before subjection to mRNA expression microarray analysis via Illumina Mouse Ref-8 V2 beadchip and GenomeStudio software V2010.2 (Illumina, Inc.). RNA hybridization to chips was performed by the Lerner Research Institute Genomics Core at the Cleveland Clinic. Microarray raw data were deposited in the NCBI Gene Expression Omnibus (GEO), accession number GSE33670.

Virus quantification

For quantification of infectious VSV in organs, mice were anesthetized with pentobarbital (150 mg/kg) and blood was removed from organs by cardiac perfusion with 10 ml of PBS. Organs were snap-frozen in liquid nitrogen, weighed, pestle/tube-homogenized (Kimble/Kontes) in 1 ml of PBS per brain or peripheral organ or 0.1 ml per pair of olfactory bulbs, and virus was titrated in 10-fold serial dilutions on Vero cells by plaque assay.

Infections were intranasal with 4 × 10^2 pfu of VSV; at 6 d.p.i., plotted as mean+SD. n = 4 mice per infected group; ND, not done. Infections were intranasal with 4 × 10^2 pfu of VSV.

Supporting Information

Figure S1 Survival of wt and Ifit2−/− mice after infection with low EMCV dose (25 pfu). Statistical significance of survival differences is indicated by p-value; n.s., not significant. (PDF)

Figure S2 Enhanced ISG and IFN-β induction in intranasally VSV-infected Ifit2−/− brain regions. IFN-β, and Ifit3/ISG56 mRNA levels in different regions of brains of uninfected or VSV-infected wt and Ifit2−/− mice at 6 d.p.i., plotted as mean+SD. n = 4 mice per infected group; ND, not done. Infections were intranasal with 4 × 10^2 pfu of VSV. (PDF)

Figure S3 Gene induction in brains after VSV or EMCV infections. A. mRNA levels of select genes in brains (without OBs) of uninfected or intranasally VSV-infected wt and Ifit2−/− mice at 6 d.p.i., plotted as mean+SD; n = 3 mice per infected group; infection was intranasal with 4 × 10^2 pfu of VSV. B, mRNA levels of select genes in brains (without OBs) of uninfected or intracranially VSV-infected wt and Ifit2−/− mice at 24 h post infection, plotted as mean±SD; n = 4 mice per infected group; infection was intracranial injection with 10 pfu of VSV. C, Ifit2, Ifit1, IFN-β and EMCV RNA levels in brains 4 days after EMCV infection (5 × 10^2 pfu, n = 3 mice per infected group). (PDF)

Figure S4 Region-selective induction of apoptosis in brains of intranasally VSV-infected Ifit2−/− mice. Ifit2−/− mice were i.n. infected with 4 × 10^2 pfu of VSV; at 6 d.p.i., adjacent sections of fixed brains were labeled to detect apoptotic cells (TUNEL) or VSV P protein (immunohistochemistry), n = 2 mice; only few regions such as striatum show positive TUNEL; infected wt brains and uninfected control brains of either genotype did not show appreciable signals, hence data not shown). (PDF)

Figure S5 VSV yields from infected wt and Ifit2−/− MEF. Immortalized MEF were treated for 16 h with 10 U/ml IFN-β and infected with VSV at moi 10. 12 hours after infection,
virus yields were determined by plaque assay. Results are plotted as means±SD on log scale, representing one of two independent experiments.

(PDF)

**Figure S6** Murine Ifit2 protein does not bind ppRNA. Single-stranded radiolabeled VSV leader RNAs (nt 1–18) with either 5′-triphosphorylated or free 5′-hydroxyl-ends (ppRNA or HO-RNA) were in *vitro* incubated with purified murine Ifit1 (=P56) or Ifit2 (=P54) proteins; formation of protein/RNA complex was detected by electrophoretic mobility shift assay.

(PDF)

**Table S1** Enhanced gene expression in brains incl. OBs of intranasally VSV-infected Ifit2−/− versus wt mice at 6 d.p.i. Wt or Ifit2−/− mice were intranasally VSV-infected with 4×10⁵ pfu, and at 2 or 6 d.p.i., brain (incl. OB) RNA expression profiles were obtained by microarray. Genes ranked by their "fold expression level in Ifit2−/− over wt at 6 d.p.i." Only genes with at least 3-fold higher expression level in Ifit2−/− are included. Note: The Ifit1/ISG56 probe of the Illumina mouse Ref-6 chip is defective and therefore the gene is not included in this list.

(PDF)

**Acknowledgments**

We thank Michifumi Yamashita and Niranjan Butchi for sharing technical expertise.

**Author Contributions**

Conceived and designed the experiments: VF JLW SR TO SAS CCB MSD HWV GCS. Performed the experiments: VF JLW SR TO SAS CCB. Analyzed the data: VF JLW SR TO SAS CCB MSD HWV GCS. Contributed reagents/materials/analysis tools: VF TO SAS CCB MSD HWV GCS. Wrote the paper: VF SAS CCB MSD HWV GCS.

**References**

1. Detje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, et al. (2009) Local type I IFN receptor signaling protects against virus spread within the central nervous system. *J Immunol* 183: 2297–2304.
2. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic, J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. *Science* 264: 1918–1921.
3. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, et al. (1995) A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. *Proc Natl Acad Sci U S A* 92: 11204–11208.
4. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441: 101–105.
5. Sato M, Suenori H, Hata N, Asajiri M, Ogasaawa K, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7 in responses to viral pathogens for IFN-alpha/beta gene induction. *Immunity* 13: 539–548.
6. Kumar H, Kawai T, Kato H, Sato S, Takahashi K, et al. (2006) Essential role of IFN-α in innate immune responses against RNA viruses. *J Exp Med* 203: 1795–1803.
7. Loewendorn A, Benedict CA (2010) Modulation of host innate and adaptive immune defenses by cytosome/galvovirus: timing is everything. *J Intern Med* 267: 403–501.
8. Altfeld M, Fadda L, Frelta D, Bhardwaj N (2011) DCs and NK cells: critical experts in the immune response to HIV-1. *Nat Rev Immunol* 11: 176–186.
9. Bender SJ, Weiss SR (2010) Pathogenesis of murine coronavirus in the central nervous system. *J Neuroimmunol* 229: 136–334.
10. Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. *Cell* 84: 431–442.
11. Schoggins JW, Wilson SJ, Pania M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* 472: 481–485.
12. Fenster A, Saikia P, Sen GC (2008) Interferon-inducible protein, P56, inhibits HIV DNA replication by binding to the viral protein E1. *EMBO J* 27: 3311–3321.
13. Wang C, Pflugheber J, Sumpter R, Jr., Sodora DL, Hui D, et al. (2003) Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. *J Virol* 77: 3898–3912.
14. Belkowski LS, Sen GC (1987) Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. *J Virol* 61: 633–660.
15. Christian YJ, Barma M, Bi Z, Reis CS (1996) Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice. *Viral Immunol* 9: 195–205.
16. Bi Z, Barma N, Komatsu T, Reis CS (1995) Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. *J Virol* 69: 6466–6472.
17. Balachandran S, Roberts PC, Brown LE, Truong H, Patnaik AK, et al. (2000) Essential role for the deoxynucleotidyl protein kinase PRK in innate immunity to viral infection. *Immunity* 13: 129–141.
18. Schulz O, Pichlmair A, Schwinkl J, Rogers NC, Scheuner D, et al. (2010) Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. *Cell Host Microbe* 7: 354–361.
19. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A (2007) Autophagy-dependent viral recognition by plasmacytoid dendritic cells. *Science* 315: 1398–1401.
20. Innamone M, Moseman EA, Toni T, Bourgi L, Junt T, et al. (2010) Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. *Nature* 465: 1079–1083.
21. Fenster F, White C, Pal S, Williams BR, Sen GC (2007) Tissue-specific and inducer-specific differential induction of ISG56 and ISG54 in mice. *J Virol* 81: 8656–8665.
22. Daffis S, Samuel MA, Keller BC, Gale M, Jr., Diamond MS (2007) Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. *PLoS Pathog* 3: e100. 
40. Simon ID, Publicover J, Rose JK (2007) Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol 81: 2078–2082.
41. Vanderhallen H, Koenen F (1997) Rapid diagnosis of encephalomyocarditis virus infections in pigs using a reverse transcription-polymerase chain reaction. J Virol Methods 66: 83–89.
42. Kapil P, Atkinson R, Ramakrishna C, Cua DJ, Bergmann CC, et al. (2009) Interleukin-12 (IL-12), but not IL-23, deficiency ameliorates viral encephalitis without affecting viral control. J Virol 83: 5978–5986.
43. Phares TW, Marques CP, Stohlman SA, Hinton DR, Bergmann CC (2011) Factors supporting intrathecal humoral responses following viral encephalomyelitis. J Virol 85: 2589–2598.